Replies to post #159080 on Biotech Values

[DewDiligence]

…Gilenya, Tecfidera and Aubagio…are priced somewhat in direct relationship to their efficacy.

That’s just a coincidence, IMO. Gilenya has the highest AWP of the three drugs (for the time being) because it was the first oral agent and hence the novelty justified a relatively high price. Aubagio hasn’t been enough of a competitive threat to force NVS to drop the price.